Scott C Robertson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Scott C Robertson has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
A N Meyer
1 shared publicationD J Donoghue
1 shared publicationDaniel J Donoghue
1 shared publicationJohn A Tynan
1 shared publication- M K Webster
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla 92093-0367, USA
1 shared publication P Y D'Avis
Department of Chemistry and Biochemistry, Center for Molecular Genetics, University of California at San Diego, La Jolla 92093-0367, USA
1 shared publication
Latest Publications
- 1 June 2000
- Published by Elsevier in Trends in Genetics
- Vol. 16 (6) , 265-271
RTK mutations and human syndromes
- 1 June 2000
- Published by Elsevier in Trends in Genetics
- Vol. 16 (6) , 265-271
RTK mutations and human syndromes
- 1 January 1998
- Vol. 9 (1) , 71-8
Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
Thanatophoric dysplasia type I (TDI) is a neonatal lethal skeletal dysplasia caused by several mutations in the extracellular domain of fibroblast growth factor receptor 3. These mutations occur either in the Ig2-Ig3 linker domain or in the extracellular juxtamembrane domain, and all involve mutation of the wild-type residue to Cys. In all cases, the presence of the mutant Cys residue allows the receptor to dimerize abnormally, resulting in ligand-independent activation. This is also manifested by increased biological signaling, increased tyrosine phosphorylation, and in vitro kinase activity associated with dimeric receptors. These results suggest that TDI is caused by Cys-mediated intermolecular disulfide bonding, leading to constitutive receptor activation as a result of these mutations. Mutations causing TDI are discussed with respect to activating mutations in other receptors that are implicated in human disease.
- 1 January 1998
- Vol. 9 (1) , 71-8
Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
Thanatophoric dysplasia type I (TDI) is a neonatal lethal skeletal dysplasia caused by several mutations in the extracellular domain of fibroblast growth factor receptor 3. These mutations occur either in the Ig2-Ig3 linker domain or in the extracellular juxtamembrane domain, and all involve mutation of the wild-type residue to Cys. In all cases, the presence of the mutant Cys residue allows the receptor to dimerize abnormally, resulting in ligand-independent activation. This is also manifested by increased biological signaling, increased tyrosine phosphorylation, and in vitro kinase activity associated with dimeric receptors. These results suggest that TDI is caused by Cys-mediated intermolecular disulfide bonding, leading to constitutive receptor activation as a result of these mutations. Mutations causing TDI are discussed with respect to activating mutations in other receptors that are implicated in human disease.